Actively Recruiting
Using a Smart Inhaler to Support Asthma Management in Adolescents With Intellectual and Developmental Disabilities
Led by Children's Hospital Los Angeles · Updated on 2025-01-20
30
Participants Needed
1
Research Sites
33 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Correct use of daily medications containing inhaled corticosteroids is key for asthma control, yet children with intellectual and developmental disabilities (IDD) face additional barriers to proper inhaler use. Smart inhalers, a novel technology that provides guidance and immediate feedback on inhaler use techniques, have been shown to enhance correct medication administration in the typically developing pediatric population, but their effectiveness has not been evaluated on the pediatric IDD population. This study aims to investigate whether daily application of smart inhalers (1) is feasible and acceptable in the IDD population, (2) improves the rate of correct medication administration, and (3) results in improvement in lung function. This effort aims to promote better asthma management in the IDD population.
CONDITIONS
Official Title
Using a Smart Inhaler to Support Asthma Management in Adolescents With Intellectual and Developmental Disabilities
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adolescents ages 10-17 years
- Diagnosis of mild-to-moderate intellectual disability (ICD-10: F70-F71) or developmental disability including autism (ICD-10: F80-89)
- Diagnosis of moderate-to-severe asthma or moderate or severe unspecified asthma (ICD-10: J45.40-J45.909)
- Parent or legal guardian willing to answer questions about their child
- Parent or legal guardian and adolescent able to understand and comply with study procedures for the entire study
- English or Spanish-speaking participants
- Not currently involved in other studies using digital inhalers
- Males and females of reproductive capability (contraception not required)
- Use of one of the following MDIs: Ventolin HFA, ProAir HFA, Advair HFA, Flovent HFA, Xopenex HFA, Symbicort HFA, Atrovent HFA, Proventil HFA, Alvesco HFA, Dulera HFA, or Asmanex HFA
You will not qualify if you...
- Limited life expectancy or co-existing disease that prevents proper diagnosis, treatment, or follow-up in the trial
- Inability or unwillingness of the individual or legal guardian to give written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
Actively Recruiting
Research Team
S
Sophia Park, MD
CONTACT
A
Alexis Deavenport-Saman, DrPH, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here